Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Clinical trial NCT02759731 · COMPLETED
Trial details
- NCT number
- NCT02759731
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-01
- Primary completion
- 2022-06-30
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.